Myeloperoxidase for guiding therapy for acute cardiac decompensation? It's heart to tell

Clinical Chemistry

Volumn 56, Issue 6, 2010, Pages 881-882

  Rudolph, Volker ^a   Baldus, Stephan ^a  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE;

ACUTE CORONARY SYNDROME; CARDIAC PATIENT; CARDIOVASCULAR RISK; DIAGNOSTIC ACCURACY; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE NECROSIS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEMODYNAMIC PARAMETERS; HUMAN; LEUKOCYTE ACTIVATION; OUTCOME ASSESSMENT; SYSTOLIC HEART FAILURE;

ACUTE DISEASE; HEART FAILURE; HUMANS; PEROXIDASE;

EID: 77952985517     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.147231     Document Type: Editorial

References (15)

1. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296:2391-2394
2. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000;275:37524-37532
3. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999;103:1547-1560
4. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004;101:13032-13037
5. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003;197: 615-624 (Pubitemid 36314656)
6. Rudolph V, Andrié RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010;16:470-474
7. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-165 (Pubitemid 47002189)
8. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-1604
9. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445 (Pubitemid 37176448)
10. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49: 1993-2000. (Pubitemid 46734639)
11. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007;49: 2364-2370 (Pubitemid 46891707)
12. Tang WH, Katz R, Brennan ML, Aviles RJ, Tracy RP, Psaty BM, Hazen SL. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol 2009;103:1269-1274
13. Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Arenja N, et al. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem 2010;56:944-951
14. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005;25:1174-1179
15. Moshal KS, Rodriguez WE, Tyagi SC. Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure. Physiol Res 2008; 57:379-384